

Prior Authorization Review Panel

CHC-MCO Policy Submission

A separate copy of this form must accompany each policy submitted for review.
Policies submitted without this form will not be considered for review.

Plan: PA Health & Wellness	Submission Date: 11/01/2021
Policy Number: PA.CP.PHAR.398	Effective Date: 01/2019 Revision Date: 10/2021

Policy Name: Moxetumomab pasudotox-tdfk (Lumoxiti)

Type of Submission – Check all that apply:

- New Policy
- Revised Policy*
- Annual Review - No Revisions
- Statewide PDL - *Select this box when submitting policies for Statewide PDL implementation and when submitting policies for drug classes included on the Statewide PDL.*

***All revisions to the policy must be highlighted using track changes throughout the document.**


Please provide any changes or clarifying information for the policy below:

4Q 2021 annual review: added HCPCS codes; reference reviewed and updated.

Name of Authorized Individual (Please type or print):

Venkateswara R. Davuluri, MD

Signature of Authorized Individual:



Clinical Policy: Moxetumomab pasudotox-tdfk (Lumoxiti)

Reference Number: PA.CP.PHAR.398

Effective Date: 01.19

Last Review Date: 10/2021

[Revision Log](#)

Description

Moxetumomab pasudotox-tdfk (Lumoxiti™) is a CD22-directed cytotoxin.

FDA Approved Indication(s)

Lumoxiti is indicated for the treatment of adult patients with relapsed or refractory hairy cell leukemia (HCL) who received at least two prior systemic therapies, including treatment with a purine nucleoside analog (PNA).

Limitation(s) of use: Not recommended in patients with severe renal impairment ($\text{CrCl} \leq 29$ mL/min).

Policy/Criteria

Provider must submit documentation (such as office chart notes, lab results or other clinical information) supporting that member has met all approval criteria.

It is the policy of health plans affiliated with PA Health & Wellness® that Lumoxiti is **medically necessary** when the following criteria are met:

I. Initial Approval Criteria

A. Hairy Cell Leukemia (must meet all):

1. Diagnosis of HCL;
2. Prescribed by or in consultation with an oncologist or hematologist;
3. Age ≥ 18 years;
4. Disease is relapsed or refractory;
5. Received at least two prior systemic therapies (*see Appendix B*), one of which must be a purine nucleoside analog (e.g., cladribine, Nipent®), unless all are contraindicated or clinically significant adverse effects are experienced;*

**Prior authorization may be required.*

6. Request meets one of the following (a or b):*
 - a. Dose does not exceed 0.04 mg/kg/dose (actual body weight) for three days of each 28-day cycle;
 - b. Dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 6 months

B. Other diagnoses/indications

1. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53.

II. Continued Therapy

A. Hairy Cell Leukemia (must meet all):

1. Currently receiving medication via Pennsylvania Health and Wellness benefit or member has previously met all initial approval criteria or the Continuity of Care policy (PA.LTSS.PHAR.01) applies;
2. Member is responding positively to therapy;
3. If request is for a dose increase, request meets one of the following (a or b):*
 - a. New dose does not exceed 0.04 mg/kg/dose (actual body weight) for three days of each 28-day cycle;
 - b. New dose is supported by practice guidelines or peer-reviewed literature for the relevant off-label use (*prescriber must submit supporting evidence*).

**Prescribed regimen must be FDA-approved or recommended by NCCN.*

Approval duration: 12 months

B. Other diagnoses/indications (must meet 1 or 2):

1. Currently receiving medication via Pennsylvania Health and Wellness benefit and documentation supports positive response to therapy or the Continuity of Care policy (PA.LTSS.PHAR.01) applies.

Approval duration: Duration of request or 6 months (whichever is less); or

2. Refer to the off-label use policy for the relevant line of business if diagnosis is NOT specifically listed under section III (Diagnoses/Indications for which coverage is NOT authorized): PA.CP.PMN.53.

III. Diagnoses/Indications for which coverage is NOT authorized:

- A.** Non-FDA approved indications, which are not addressed in this policy, unless there is sufficient documentation of efficacy and safety according to the off label use policy – PA.CP.PMN.53 evidence of coverage documents.

IV. Appendices/General Information

Appendix A: Abbreviation/Acronym Key

CLS: Capillary Leak Syndrome	HCL: hairy cell leukemia
CR: complete response	HUS: Hemolytic Uremic Syndrome
FDA: Food and Drug Administration	PNA: purine nucleoside analog

Appendix B: Therapeutic Alternatives

This table provides a listing of preferred alternative therapy recommended in the approval criteria. The drugs listed here may not be a formulary agent for all relevant lines of business and may require prior authorization.

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
cladribine (<i>purine analog</i>)	Adult dose: 0.09 mg/kg IV QD for 7 days (off-label SC dosing has been evaluated).	0.09 mg/kg/day
Nipent® (pentostatin) (<i>purine analog</i>)	Adult dose: 4 mg/m ² IV once every other week up to 6 months if failure to respond.	4 mg/m ² /dose once every other week

Drug Name	Dosing Regimen	Dose Limit/ Maximum Dose
Intron A [®] (interferon alfa-2b)	Adult dose: 2 million units/m ² IM or SC 3 times a week for up to 6 months if failure to respond.	2 million units/m ² /dose
Rituxan [®] (rituximab)	Off-label adult dose: 375 mg/m ² IV weekly up to 10 weeks has been reported. (Micromedex)	Varies
Imbruvica [®] (ibrutinib)	Off-label adult dose: 420 mg PO QD in 28-day cycles until unacceptable toxicity or progressive disease. (Jones 2016)	Varies
Zelboraf [®] (vemurafenib)	Off-label adult dose: 960 mg PO BID for up to 24 weeks. (Clinical Pharmacology)	Varies

Therapeutic alternatives are listed as Brand name[®] (generic) when the drug is available by brand name only and generic (Brand name[®]) when the drug is available by both brand and generic.

Appendix C: Contraindications/Boxed Warnings

- Contraindication(s): none reported
- Boxed warning(s): capillary leak syndrome (CLS), hemolytic uremic syndrome (HUS)

Appendix D: General Information

The National Comprehensive Cancer Network (NCCN) HCL treatment recommendations:

- First-line therapy: purine analogs (cladribine, Nipent[®] (pentostatin)).
- Second-line therapy for relapse/refractory or progressive disease:
 - Disease relapse ≥ 2 years after achieving CR to initial therapy:
 - Retreatment with the same purine analog ± rituximab
 - An alternate purine analog ± rituximab
 - Rituximab monotherapy if unable to receive a purine analog
 - Disease relapse < 2 years or less than CR after initial therapy:
 - An alternative purine analog ± rituximab
 - Peginterferon-alfa 2a (may be substituted for other interferon preparations)
 - Rituximab monotherapy if unable to receive purine analog
 - Zelboraf[®] (vemurafenib)
- Third-line therapy and beyond for progressive disease:
 - Zelboraf[®] (vemurafenib) ± rituximab
 - Imbruvica[®] (ibrutinib)
 - Lumoxiti

V. Dosage and Administration

Indication	Dosing Regimen	Maximum Dose
HCL	0.04 mg/kg IV on Days 1, 3, and 5 of each 28-day cycle. Continue treatment for maximum of 6 cycles, disease progression, or unacceptable toxicity.	0.04 mg/kg/dose (actual body weight)

VI. Product Availability

Single-dose vial: 1 mg

VII. References

1. Lumoxiti Prescribing Information. Wilmington, DE: AstraZeneca Pharmaceuticals LP; April 2020. Available at: <https://www.lumoxiti.com/>. Accessed August 11, 2021.
2. National Comprehensive Cancer Network Drugs and Biologics Compendium. Available at nccn.org. Accessed August 11, 2021.
3. National Comprehensive Cancer Network Guidelines. Hairy Cell Leukemia Version 2.2021. Available at: https://www.nccn.org/professionals/physician_gls/pdf/hairy_cell.pdf. Accessed August 11, 2021.

Coding Implications

Codes referenced in this clinical policy are for informational purposes only. Inclusion or exclusion of any codes does not guarantee coverage. Providers should reference the most up-to-date sources of professional coding guidance prior to the submission of claims for reimbursement of covered services.

HCPCS Codes	Description
J9313	Injection, moxetumomab pasudotox-tdfk, 0.01 mg

Reviews, Revisions, and Approvals	Date	P&T Approval Date
Policy created	01.19	
4Q 2019 annual review: No changes per Statewide PDL implementation 01-01-2020	10/30/19	
4Q 2020 annual review: Updated dosing and reviewed and updated references.	08/20	11/20
4Q 2021 annual review: added HCPCS codes; reference reviewed and updated.	10/2021	